Effectiveness of lidocaine patches in the treatment of post-herpetic neuralgia on the face: a systematic review and meta-analysis
Keywords:Anesthetics; Lidocaine; Herpes Zoster; Neuralgia.
The post-herpetic neuralgia (PHN) is one of the most chalenging neuropathies to resolve. There are many treatment options with varying degrees of effectiveness. This paper conducts a systematic review of the literature on lidocaine patches in the treatment of these neuralgia. A systematic review according to the PRISMA guidelines on lidocaine patches in the treatment of postherpetic neuralgia. The PROPERO registration has been carried out. A meta-analysis was performed with RevMan 5.3. Nine articles were included according to criteria. A table of excluded articles and their reason was carried out. Lidocaine patches are effective in treating post-herpetic neuralgia and are safer than other treatments, making them available for elderly patients with co-morbid conditions when other treatments cannot be used due to side effects. Lidocaine patches should be considered the first line therapy in the treatment of post-herpetic neuralgia of the face because of their safety and cost-benefit ratio.
Baron, R., Mayoral, V., Leijon, G., Binder, A., Steigerwald, I., & Serpell, M. (2009) 5% Lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: An open-label, non-inferiority two-stage RCT study. Curr Med Res Opin. 25(7):1663–76.
Baron, R., Mayoral, V., Leijon, G., Binder, A., Steigerwald, I., & Serpell, M. (2009) Efficacy and safety of 5% lidocaine (lignocaine) medicated plaster in comparison with pregabalin in patients with postherpetic neuralgia and diabetic polyneuropathy: Interim analysis from an open-label, two-stage adaptive, randomized, controlled trial. Clin Drug Investig. 29(4):231–41.
Baron, R., Mayoral, V., Leijon, G., Binder, A., Steigerwald, I., & Serpell, M. (2009) Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy. Curr Med Res Opin. 25(7):1677–87.
Binder, A., Bruxelle, J., Rogers, P., Hans, G., Bösl, I., & Baron, R. (2009) Topical 5% lidocaine (lignocaine) medicated plaster treatment for post-herpetic neuralgia: Results of a double-blind, placebo-controlled, multinational efficacy and safety trial. Clin Drug Investig. 29(6):393–408.
Binder, A., Rogers, P., Hans, G., & Baron, R. (2016) Impact of topical 5% lidocaine-medicated plasters on sleep and quality of life in patients with postherpetic neuralgia. Pain Manag. 6(3):229–39.
Bruckenthal, P., & Barkin, R. L. (2013) Options for treating postherpetic neuralgia in the medically complicated patient. Vol. 9, Therapeutics and Clinical Risk Management. 329–40.
Bursi, R., Piana, C., Grevel, J., Huntjens, D., & Boesl, I. (2017) Evaluation of the Population Pharmacokinetic Properties of Lidocaine and its Metabolites After Long-Term Multiple Applications of a Lidocaine Plaster in Post-Herpetic Neuralgia Patients. Eur J Drug Metab Pharmacokinet.42(5):801–14.
Campbell, B. J., Rowbotham, M., Davies, P. S., Jacob, P., & Benowitz, N. L. (2002) Systemic absorption of topical lidocaine in normal volunteers, patients with post-herpetic neuralgia, and patients with acute herpes zoster. J Pharm Sci. 91(5):1343–50.
Casale, R., Di Matteo, M., Minella, C. E., Fanelli, G., & Allegri, M. (2014) Reduction of painful area as new possible therapeutic target in post-herpetic neuropathic pain treated with 5% lidocaine medicated plaster: A case series. Journal of Pain Research. 7, 353–7.
Clère, F., Delorme-Morin, C., George, B., Navez, M., Rioult, B., Tiberghien-Chatelain, F., et al. (2011) 5 Lidocaine medicated plaster in elderly patients with postherpetic neuralgia: Results of a compassionate use programme in france. Drugs and Aging. 28(9):693–702.
Dakin, H., Nuijten, M., Liedgens, H., Nautrup, B. P. (2007) Cost-Effectiveness of a Lidocaine 5% Medicated Plaster Relative to Gabapentin for Postherpetic Neuralgia in the United Kingdom. Clin Ther. 29(7):1491–507.
Fashner, J., & Bell, A. (2011) Herpes zoster and postherpetic neuralgia: prevention and management. Am Fam Physician. 2011;83(12):1432–7.
Galer, B. S., Rowbotham, M. C., Perander, J., & Friedman, E. (1999) Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: Results of an enriched enrollment study. Pain. 80(3):533–8.
Goddard, J. M., & Reaney, R. L. (2018) Lidocaine 5%–medicated plaster (Versatis) for localised neuropathic pain: results of a multicentre evaluation of use in children and adolescents. Br J Pain. 12(3):189–93.
Gore, M., Sadosky, A., Tai, K. S., & Stacey, B. (2007) A Retrospective Evaluation of the Use of Gabapentin and Pregabalin in Patients with Postherpetic Neuralgia in Usual-Care Settings. Clin Ther. 29(8):1655–70.
Gudin, J., Fudin, J., Wang, E., Haylon, T., Patel, K., & Goss, T. F. (2019) Treatment patterns and medication use in patients with postherpetic neuralgia. J Manag Care Spec Pharm. 25(12):1387–96.
Hans, G., Sabatowski, R., Binder, A., Boesl, I., Rogers, P., & Baron, R. (2009) Efficacy and tolerability of a 5% lidocaine medicated plaster for the topical treatment of post-herpetic neuralgia: Results of a long-term study. In: Current Medical Research and Opinion. 1295–305.
Higgins, J. P. T., Altman, D. G., Gøtzsche, P. C., Jüni, P., Moher, D., Oxman, A. D., et al. (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 343(7829).
Katz, N. P., Gammaitoni, A. R., Davis, M. W., Dworkin, R. H., Avery, J., Burick, T., et al. (2002) Lidocaine patch 5% reduces pain intensity and interference with quality of life in patients with postherpetic neuralgia: An effectiveness trial. Pain Med. 3(4):324–32.
Kirson, N. Y., Ivanova, J. I., Birnbaum, H. G., Wei, R., Kantor, E., Amy Puenpatom, R., et al. (2010)a Descriptive analysis of Medicaid patients with postherpetic neuralgia treated with lidocaine patch 5%. J Med Econ. 13(3):472–81.
Kirson, N. Y., Ivanova, J. I., Birnbaum, H. G., Wei, R., Kantor, E., Puenpatom, R. A., et al. (2010)b Comparing healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% versus gabapentin or pregabalin. J Med Econ. 13(3):482–91.
Kontić, M., Vicic-Hudorović, V., & Hudorović, N. (2016) Treatment of postherpetic neuralgia with 5% topical lidocaine plaster - Experience from a small county hospital: Case report. Acta Clin Croat. 55(4):655–8.
Laurent, B., Vicaut, E., Leplège, A., Bloch, K., & Leutenegger, E. (2014) Prevalence and impact on quality of life of post-herpetic neuralgia in French medical centers specialized in chronic pain management: The ZOCAD study. Med Mal Infect.44(11–12):515–24.
Liedgens, H., Hertel, N., Gabriel, A., Nuijten, M., Dakin, H., Mitchell, S., et al. (2008) Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: A German perspective. Vol. 28, Clinical Drug Investigation. 583–601.
Lin, P. L., Fan, S. Z., Huang, C. H., Huang, H. H., Tsai, M. C., Lin, C. J., et al. (2008) Analgesic Effect of Lidocaine Patch 5% in the Treatment of Acute Herpes Zoster: A Double-Blind and Vehicle-Controlled Study. Reg Anesth Pain Med. 33(4):320–5.
Lu, L, Suo, L, Li, J., & Pang, X. (2018) A retrospective survey on herpes zoster disease burden and characteristics in Beijing, China. Hum Vaccines Immunother. 2018;14(11):2632–5.
Malec-Milewska, M., Horosz, B., Sękowska, A., Kolęda, I., Kucia, H., & Kosson, D. (2015) 5% lidocaine medicated plasters vs. Sympathetic nerve blocks as a part of multimodal treatment strategy for the management of postherpetic neuralgia: A retrospective, consecutive, case-series study. Neurol Neurochir Pol. 49(1):24–8.
Metsker, O., Magoev, K., Yanishevskiy, S., Yakovlev, A., Kopanitsa, G., & Zvartau N. Identification of diabetes risk factors in chronic cardiovascular patients. In: Studies in Health Technology and Informatics. 136–41.
Nalamachu, S., Wieman, M., Bednarek, L., & Chitra, S. (2013) Influence of anatomic location of lidocaine patch 5% on effectiveness and tolerability for postherpetic neuralgia. Patient Prefer Adherence. 7:551–7.
Obradovic, M., Vanden, B. H., & Liedgens, H. (2014) Cost-Effectiveness of the Lidocaine 5% Medicated Plaster Verse Pregabalin and Amitriptyline for the Treatment of Post-Herpetic Neuralgia In the Netherlands. Value Heal. 17(7):A531.
Pedrosa, V. de C., A., Silva, J. G. A. (2013) Medicina baseada em evidências Avaliação do risco de viés de ensaios clínicos randomizados pela ferramenta da colaboração Cochrane. 18, Diagn Tratamento. 2013.
Pereira, M., Saúde TG-E e S de, U. (2014) Heterogeneidade e viés de publicação em revisões sistemáticas. SciELO Public Heal.
Pickering, G., Pereira, B., Clère, F., Sorel, M., de Montgazon, G., Navez, M., et al. (2014) Cognitive function in older patients with postherpetic neuralgia. Pain Pract 14(1). https://pubmed.ncbi.nlm.nih.gov/23701810/
Rehm, S., Binder, A., & Baron, R. (2010) Post-herpetic neuralgia: 5% lidocaine medicated plaster, pregabalin, or a combination of both A randomized, open, clinical effectiveness study. Curr Med Res Opin. 26(7):1607–19.
Ritchie, M., Liedgens, H., & Nuijten, M. (2010) Cost effectiveness of a lidocaine 5% medicated plaster compared with pregabalin for the treatment of postherpetic neuralgia in the UK: A Markov model Analysis. Clin Drug Investig. 30(2):71–87.
Rowbotham, M. C., Davies, P. S., Verkempinck, C., & Galer, B. S. (1996) Lidocaine patch: Double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain. 65(1):39–44.
Sabatowski, R., et al. Treatment of postherpetic neuralgia with 5% lidocaine medicated plaster in elderly patients–subgroup analyses from three European clinical trials. Curr Med Res Opin. 33(3):595–603.
Sabatowski R, et al.. (2012) Safety and efficacy outcomes of long-term treatment up to 4 years with 5 lidocaine medicated plaster in patients with post-herpetic neuralgia. Curr Med Res Opin. 28(8):1337–46.
Smith A, et al. (2021) Effect of an Online Reimbursement Application System on Prescribing of Lidocaine 5% Medicated Plaster in the Republic of Ireland. Appl Health Econ Health Policy.19(1):133–40.
Wang, Y. F., et al. (2020) Persistence of pregabalin treatment in Taiwan: A nation-wide population-based study. J Headache Pain. 21(1).
Wasner, G, et al. (2005) Postherpetic neuralgia: Topical lidocaine is effective in nociceptor-deprived skin. J Neurol. 252(6):677–86.
Wehrfritz, A., et al. (2011) Differential effects on sensory functions and measures of epidermal nerve fiber density after application of a lidocaine patch (5%) on healthy human skin. Eur J Pain. 15(9):907–12.
How to Cite
Copyright (c) 2021 Ricardo Grillo; Marília Coelho Oliveira Dutra Leal; Antônio Augusto Campanha; Claudio Roberto Pacheco Jodas; Rubens Gonçalves Teixeira
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.